| |
New Healthcare Service Targets Europe
Healthcare information giant IMS Health has this week announced the launch of new consulting capabilities for European clients, offering private and public sector clients evidence-based insights into the cost, value and anticipated consequences of therapies and treatment options.
Initially the service will make use of health economics model evaluations, cost-of-illness studies, disease management models and budget impact analyses, and will make use of the specific expertise of two recently acquired companies: GYD Institute, based in France, and Belgium-based HEDM (Health Economics and Disease Management). It will also be available to US and Canadian clients.
'In Europe', says HEDM founder Professor Lieven Annemans, 'there is increasing pressure from government agencies to control, or even lower, the healthcare costs that they are paying. As a result, there is a growing need for accurate comparative analyses of alternative treatment options: what is the cost of each, and what are the anticipated health consequences?'
Prof Annemans is the current President of ISPOR, the International Society of Pharmacoeconomics and Outcomes Research, at whose 7th Annual Congress in Hamburg IMS will be presenting on these topics later this month. The company is also hosting a seminar in Bruges, Belgium in November for healthcare industry decision makers. Details of these events and of the company generally are available via www.imshealth.com
|
